Anthony Hawkridge

Summary

Publications

  1. doi request reprint Prospects for a new, safer and more effective TB vaccine
    Tony Hawkridge
    Aeras Global TB Vaccine Foundation, Africa Office, Belmont Square, Belmont Road, Rondebosch, Cape Town, 7700, South Africa
    Paediatr Respir Rev 12:46-51. 2011
  2. pmc The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa
    Hassan Mahomed
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    PLoS ONE 6:e17984. 2011
  3. doi request reprint Phenotypic variability in childhood TB: implications for diagnostic endpoints in tuberculosis vaccine trials
    Humphrey Mulenga
    South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa
    Vaccine 29:4316-21. 2011
  4. ncbi request reprint Determining causes of mortality in children enrolled in a vaccine field trial in a rural area in the Western Cape Province of South Africa
    Sizulu Moyo
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    J Paediatr Child Health 43:178-83. 2007
  5. pmc Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa
    Mark Hatherill
    School of Child and Adolescent Health, University of Cape Town, Anzio Road, Cape Town, 7925, South Africa
    Bull World Health Organ 88:312-20. 2010
  6. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
  7. pmc Advances in childhood immunisation in South Africa: where to now? Programme managers' views and evidence from systematic reviews
    Charles Shey Wiysonge
    Vaccines for Africa Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    BMC Public Health 12:578. 2012
  8. doi request reprint Developing vaccinology expertise for Africa: six years and counting
    Charles Shey Wiysonge
    Vaccines for Africa Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Vaccine 29:5821-3. 2011
  9. pmc The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults
    Brian Abel
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, UCT Health Sciences, Anzio Road, Observatory 7925, Cape Town, South Africa
    Am J Respir Crit Care Med 181:1407-17. 2010
  10. ncbi request reprint The impact of a change in bacille Calmette-Guérin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa
    Hassan Mahomed
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Pediatr Infect Dis J 25:1167-72. 2006

Collaborators

Detail Information

Publications13

  1. doi request reprint Prospects for a new, safer and more effective TB vaccine
    Tony Hawkridge
    Aeras Global TB Vaccine Foundation, Africa Office, Belmont Square, Belmont Road, Rondebosch, Cape Town, 7700, South Africa
    Paediatr Respir Rev 12:46-51. 2011
    ..Prospects for at least one new licensed TB vaccine within the next 5-10 years appear reasonable. This article explores some of the issues around the development of new vaccines against TB and details the leading candidates...
  2. pmc The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa
    Hassan Mahomed
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    PLoS ONE 6:e17984. 2011
    ..This study was conducted in a high tuberculosis (TB) burden area in Worcester, South Africa, with a notified all TB incidence rate of 1,400/100,000...
  3. doi request reprint Phenotypic variability in childhood TB: implications for diagnostic endpoints in tuberculosis vaccine trials
    Humphrey Mulenga
    South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa
    Vaccine 29:4316-21. 2011
    ....
  4. ncbi request reprint Determining causes of mortality in children enrolled in a vaccine field trial in a rural area in the Western Cape Province of South Africa
    Sizulu Moyo
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    J Paediatr Child Health 43:178-83. 2007
    ....
  5. pmc Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa
    Mark Hatherill
    School of Child and Adolescent Health, University of Cape Town, Anzio Road, Cape Town, 7925, South Africa
    Bull World Health Organ 88:312-20. 2010
    ....
  6. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
    ..Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control...
  7. pmc Advances in childhood immunisation in South Africa: where to now? Programme managers' views and evidence from systematic reviews
    Charles Shey Wiysonge
    Vaccines for Africa Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    BMC Public Health 12:578. 2012
    ..We assessed challenges and enablers for the programme in South Africa, as we approach the 2015 deadline for the Millennium Development Goals...
  8. doi request reprint Developing vaccinology expertise for Africa: six years and counting
    Charles Shey Wiysonge
    Vaccines for Africa Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Vaccine 29:5821-3. 2011
    ....
  9. pmc The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults
    Brian Abel
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, UCT Health Sciences, Anzio Road, Observatory 7925, Cape Town, South Africa
    Am J Respir Crit Care Med 181:1407-17. 2010
    ..AERAS-402 is a novel tuberculosis vaccine designed to boost immunity primed by bacillus Calmette-Guérin (BCG), the only licensed vaccine...
  10. ncbi request reprint The impact of a change in bacille Calmette-Guérin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa
    Hassan Mahomed
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Pediatr Infect Dis J 25:1167-72. 2006
    ....
  11. pmc Evaluation of the quality of informed consent in a vaccine field trial in a developing country setting
    Deon Minnies
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    BMC Med Ethics 9:15. 2008
    ..The aim of the study was to evaluate the quality of consent in the case control study, and to identify factors that may influence the quality of consent. Cross-sectional study conducted over a 4 month period...
  12. ncbi request reprint Clinical studies of TB vaccines
    Anthony Hawkridge
    Aeras Global TB Vaccine Foundation, Rondebosch, Cape Town, Western Cape, South Africa
    Hum Vaccin 5:773-6. 2009
    ..Over the last decade significant progress has been made in assessing potential sites and assisting them to develop the necessary capacity to participate in future efficacy trials of new TB vaccines...
  13. pmc Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns
    Benjamin M N Kagina
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 182:1073-9. 2010
    ..Immunogenicity of new tuberculosis (TB) vaccines is commonly assessed by measuring the frequency and cytokine expression profile of T cells...